New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials

Sydney, Aus, Mar 3, 2017 – (ACN Newswire) – Frost & Sullivan today released its latest white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse; facilitated by the availability of vast treatment-naive patient pools, exceptional …